Sullivan & Cromwell
Brad King
- Deals
- 3
- Latest
- Jul 2026
- Most deals in
- Biotech
Firm
- Sullivan & Cromwell Law firm · 2026 · 3 deals
Often works with
- Rachel Yu 2 deals together
- Elizabeth Cheung 2 deals together
- Alexander Bavis 2 deals together
- Matt Hurd 1 deal together
- Spencer Nord 1 deal together
Deals
Deals dated after 30 September 2026 are still being collected.
Columns
| Jul 2026 | AtaiBeckley | – | Eli Lilly and Company | Acquisition | Legal adviser to Apeiron Investment Group (target) | Announced | 2,800.0 | Biotech+2 | Eli Lilly and Company acquisition of AtaiBeckley |
| Jul 2026 | Avere Therapeutics | – | – | Placement | Legal adviser to Hansoh Pharma | Announced | 320.0 | Biotech+1 | Avere Therapeutics placement |
| Jul 2026 | Avere Therapeutics | – | NextCure | Merger | Legal adviser to Hansoh Pharma | Announced | – | Biotech+1 | NextCure and Avere Therapeutics merger |
Deals where Brad King is named on the firm's deal team, by the firm or the press.